Abstract: The invention concerns polymorphisms in the CXCL5 gene and the concentration of epithelial neutrophil activating peptide (ENA-78) in patients. The invention also pertains to methods and systems for detecting such polymorphisms. The invention further relates to the use of such methods and systems in the diagnosis, prognosis, and treatment selection for inflammatory disorders associated with elevated ENA-78 concentrations.

Abstract: 5-LO is expressed in the monocyte/macrophages (mono/mac) and foam cells of atherosclerotic lesions and is differentially expressed in CAST and CON6 mice relative to B6 mice. Mice heterozygous for a null mutation of 5-LO, when placed on an LDLR?/? background, have dramatically reduced atherosclerosis as compared to control LDLR?/? mice. In a genetic epidemiologic study, it is found that a common 5-LO polymorphism is strongly associated with carotid artery intima-media thickness (IMT) and coronary artery disease patients. These results indicate that 5-LO and the leukotriene biosynthetic pathway is a major contributor to atherogenesis in animal models, and in atherosclerosis susceptibility in humans.

Abstract: 5-LO is expressed in the monocyte/macrophages (mono/mac) and foam cells of atherosclerotic lesions and is differentially expressed in CAST and CON6 mice relative to B6 mice. Mice heterozygous for a null mutation of 5-LO, when placed on an LDLR−/− background, have dramatically reduced atherosclerosis as compared to control LDLR−/− mice. In a genetic epidemiologic study, it is found that a common 5-LO polymorphism is strongly associated with carotid artery intima-media thickness (IMT) and coronary artery disease patients. These results indicate that 5-LO and the leukotriene biosynthetic pathway is a major contributor to atherogenesis in animal models, and in atherosclerosis susceptibility in humans.